Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In human CaP, gene fusion between androgen responsive regulatory elements at the 5'-untranslated region of TMPRSS2 and ETS-related genes (ERG) is present in at least 50% of prostate tumors.
|
31303963 |
2019 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We also found that the interstitial region between TMPRSS2 and ERG harbors at least one prostate tumor suppressor, ETS2, whose loss contributes to prostate cancer progression.
|
29786791 |
2018 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The fusion of the androgen-regulated gene TMPRSS2 and the oncogene ERG (TMPRSS2:ERG or T2E) is common in PCa, and prostate tumors that harbor the gene fusion are believed to represent a distinct disease subtype.
|
27753122 |
2017 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Taken together, our work shows that overexpressed ERG co-opts master transcription factors to deploy a unique cis-regulatory landscape, inducing a druggable dependency on NOTCH signaling in T2E-positive prostate tumors.
|
28783165 |
2017 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men.
|
27814612 |
2017 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Expert commentary: The new additions to the 2016 WHO tumor classification, which include pathological definition of Intraductal carcinoma of the prostate (IDC-P) and of a new grading system for PCa, as well as identification of molecular markers, such as TMPRSS2-ERG and AR-V7, may pave the way to personalized therapy for patients with prostate tumors.
|
28598696 |
2017 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Utilizing gene expression datasets, from matched normal and prostate tumor epithelial cells, an association of NOTCH transcription factors with <i>ERG</i> expression status was identified, confirming that <i>NOTCH</i> factors are direct transcriptional targets of ERG.
|
28607007 |
2017 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These novel insights will enhance the understanding of the mechanistic functions of ERG in prostate tumor biology and towards development of early targeted therapeutic strategies for prostate cancer.
|
28439080 |
2017 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Taken together, our work shows that overexpressed ERG co-opts master transcription factors to deploy a unique cis-regulatory landscape, inducing a druggable dependency on NOTCH signaling in T2E-positive prostate tumors.
|
28783165 |
2017 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors.
|
27191272 |
2016 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
TMPRSS2-ERG gene fusions found in human prostate tumors are a hallmark of chromoplexy.
|
26751641 |
2016 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Ets related gene (ERG) is a transcription factor that is overexpressed in 40% of prostate tumors due to a gene fusion between ERG and TMPRSS2.
|
27626314 |
2016 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
|
27223260 |
2016 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.
|
27783944 |
2016 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Among 131 primary prostate tumors which were primarily from European American patients, TDRD1 is over-expressed in 68% of samples, while ERG is overexpressed in 48% of samples, suggesting an additional ERG-independent mechanism of TDRD1 overexpression.
|
27272765 |
2016 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Integrative molecular profiling of routine clinical prostate cancer specimens.
|
25735316 |
2015 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We determined that ERG activates the transcriptional program regulated by YAP1 of the Hippo signaling pathway and found that prostate-specific activation of either ERG or YAP1 in mice induces similar transcriptional changes and results in age-related prostate tumors.
|
26058078 |
2015 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We have quantitatively analyzed the mRNA levels of TMPRSS2-ERG, ERG, PTEN, and AR (n = 83), as well as ERG immunostaining (n = 78) in a series of prostate tumors.
|
25939480 |
2015 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The TMPRSS2-ERG positive status correlates with moderate to poorly differentiated prostate tumors and it is considered as unfavorable disease predictor.
|
25753984 |
2015 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In contrast, PTEN and ERG common driver alterations in CaP were significantly lower in AA prostate tumors compared to prostate tumors from CA.
|
26844274 |
2015 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Collectively, our data suggest that ERG sensitizes prostate tumor cells to neurotransmitter receptor agonists like nicotine.
|
26310325 |
2015 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
When compared to immunohistochemistry, TMPRSS2-ERG fusion-negative and fusion-positive prostate tumours were correctly classified.
|
24931216 |
2014 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This study delineates the global proteome for prostate tumors stratified by ERG expression status.
|
24115221 |
2014 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth.
|
25088707 |
2014 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This report describes a novel mouse model that overexpresses ERG and lacks PTEN with the majority of mice developing prostate tumors by 6 mo.
|
25007053 |
2014 |